Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Has Average Target Price of $11.50

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $11.50.

A number of analysts have recently commented on KPTI shares. Wall Street Zen downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Piper Sandler decreased their price target on Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Royal Bank Of Canada restated an “outperform” rating and issued a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Finally, Weiss Ratings cut shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $0.87 on Friday. The stock has a market cap of $19.66 million, a PE ratio of -0.07 and a beta of 1.04. The firm has a fifty day moving average price of $2.33 and a 200 day moving average price of $6.32. Karyopharm Therapeutics has a 1 year low of $0.85 and a 1 year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The business had revenue of $33.43 million for the quarter, compared to the consensus estimate of $32.19 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -4.7 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Hsbc Holdings PLC purchased a new position in Karyopharm Therapeutics in the first quarter valued at $66,000. Headlands Technologies LLC purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $118,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Karyopharm Therapeutics during the 1st quarter valued at about $108,000. Bank of New York Mellon Corp acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $559,000. Finally, Royal Bank of Canada grew its position in shares of Karyopharm Therapeutics by 4.1% during the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after acquiring an additional 2,399 shares during the period. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on nuclear transport, particularly the role of exportin 1 (XPO1) in regulating the movement of proteins and RNA between a cell’s nucleus and cytoplasm.

Karyopharm’s primary product is selinexor, an oral selective inhibitor of XPO1. In the United States, selinexor is marketed as XPOVIO for certain patients with multiple myeloma and diffuse large B-cell lymphoma, in combination with specified therapies or under defined treatment circumstances.